- Home
- MPU vs ABOS Comparison
MPU vs ABOS Comparison
Compare MPU & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPU
- ABOS
- Stock Information
- Founded
- MPU 1989
- ABOS 1996
- Country
- MPU Singapore
- ABOS United States
- Employees
- MPU N/A
- ABOS N/A
- Industry
- MPU Transportation Services
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- MPU Consumer Discretionary
- ABOS Health Care
- Exchange
- MPU Nasdaq
- ABOS Nasdaq
- Market Cap
- MPU 78.8M
- ABOS 90.3M
- IPO Year
- MPU 1998
- ABOS 2021
- Fundamental
- Price
- MPU $2.68
- ABOS $1.57
- Analyst Decision
- MPU
- ABOS Strong Buy
- Analyst Count
- MPU 0
- ABOS 3
- Target Price
- MPU N/A
- ABOS $6.33
- AVG Volume (30 Days)
- MPU 1.6M
- ABOS 843.7K
- Earning Date
- MPU 08-13-2025
- ABOS 08-12-2025
- Dividend Yield
- MPU N/A
- ABOS N/A
- EPS Growth
- MPU N/A
- ABOS N/A
- EPS
- MPU N/A
- ABOS N/A
- Revenue
- MPU $35,228,600.00
- ABOS N/A
- Revenue This Year
- MPU N/A
- ABOS N/A
- Revenue Next Year
- MPU N/A
- ABOS N/A
- P/E Ratio
- MPU N/A
- ABOS N/A
- Revenue Growth
- MPU 305.32
- ABOS N/A
- 52 Week Low
- MPU $0.49
- ABOS $0.86
- 52 Week High
- MPU $2.78
- ABOS $3.60
- Technical
- Relative Strength Index (RSI)
- MPU 70.42
- ABOS 63.47
- Support Level
- MPU $1.82
- ABOS $1.54
- Resistance Level
- MPU $2.78
- ABOS $1.78
- Average True Range (ATR)
- MPU 0.36
- ABOS 0.12
- MACD
- MPU 0.04
- ABOS 0.02
- Stochastic Oscillator
- MPU 92.06
- ABOS 66.67
About MPU Mega Matrix Corp.
Mega Matrix Inc is a holding company. It operates through its two subsidiaries Mega Metaverse Corp (Mega) and JetFleet Management Corp (JMC). The Company has two business segments which are comprised of : ETH staking business and The leasing of regional aircraft to foreign and domestic regional airlines. The majority of the company's revenue is earned through Leasing business segment. The company operates in USA and Canada, Asia-Pacific, Europe, Middle East and Africa, and Latin America.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.